YSG
NYSE · Consumer Cyclical · Specialty Retail · CN
Next report
Analyst consensus
- Next report date
- Nov 24, 2026
- EPS estimate
- —
- Revenue estimate
- $166.1M
Latest reported
- Last report date
- Sep 2, 2026
- EPS actual
- -$0.16
- EPS estimate
- —
- Revenue actual
- $168.2M
- Revenue estimate
- $168.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -482.1%
- Revenue beats (12Q)
- 3
Q2 FY2026 · Sep 2, 2026
AI summary of management’s prepared remarks and analyst Q&A · For informational purposes only, not investment advice
Management highlights
- Strategic Shift to Skincare: The company has fundamentally shifted its revenue mix toward skincare, which now accounts for over 70% of total revenues, driving sustainable growth despite broader industry headwinds.
- R&D and Innovation: R&D expenses remained stable at 3.3% of total net revenues. The Global Innovation R&D Center received national high-tech enterprise recognition, and Dr. Wu published three studies in international SCI journals validating scientific capabilities.
- Product Portfolio Expansion: New product launches included Galanique’s reviving eye cream, Dr. Wu’s essence masks for oil control and hydration, and Yves Long’s second-generation VITAL-DU collection.
- Brand Engagement: High-impact campaigns included Dr. Wu’s CCTV.com live stream (178 million viewers), Galanique’s pop-up in Sanya, and Yves Long’s participation in the British Beauty Festival.
- Profitability Optimization: Growth margin was impacted by one-time inventory provisions in color cosmetics; underlying margins were stable. Selling and marketing expense ratios rose due to strategic investments in Douyin and brand building.
- Operational Efficiency: Fulfillment expenses decreased as a percentage of revenue (to 4.9%) due to logistics improvements. AI integration is being accelerated across operational workflows to drive productivity.
- Leadership Update: Ms. Wang Li appointed as Chief Financial Officer, bringing extensive experience in the consumer beauty industry to support cost structure optimization.
Guidance
- Third Quarter 2026 Total Net Revenues: Expected between RMB 898.6 million and RMB 998.4 million.
- This represents a year-over-year decrease of approximately 0% to 10%.
- Management noted these forecasts are preliminary and subject to change based on market conditions.
Segment performance
Total net revenues increased 5.1% year-over-year to RMB 1.14 billion. Skincare brands delivered exceptional performance, with revenues growing 40.4% year-over-year and now representing 71.5% of total net revenues. Conversely, color cosmetics brands saw a significant decline, with revenues dropping 35.8% year-over-year due to proactive portfolio optimization and SKU rationalization.
Risks & headwinds
- Industry Headwinds: Broad-based challenges in the domestic beauty industry, including growth deceleration among competitors.
- Consumer Behavior: Increasing promotional fatigue and more rational consumer behavior impacting sales effectiveness during major shopping festivals.
- Competitive Landscape: Intense competition leading to higher traffic acquisition costs, particularly on key digital platforms like Douyin.
- Inventory Risk: Proactive SKU rationalization in color cosmetics led to higher inventory provisions, impacting short-term margins.
Analyst Q&A
Q: Analyst asked about channel expansion strategies for skincare brands and how management plans to address rising online traffic costs and improve marketing efficiency. / A: Management outlined a shift toward diversified channels beyond core online platforms (Tmall/Douyin) to include B2B, offline distribution, duty-free, and professional/OTC channels, which offer lower traffic costs and healthier profitability. To combat rising digital traffic costs, the company is reallocating resources to high-growth skincare brands (now >70% of revenue), expanding into lower-cost B2B/professional channels, and leveraging AI and improved CRM/content strategies to enhance budget efficiency without cutting essential investment.
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 24, 2026